Omega-3

Omega-3 fatty acids are essential polyunsaturated fatty acids, primarily EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), found in fish oil and marine sources, plus ALA (alpha-linolenic acid) from plant sources. They serve critical roles in brain function, cardiovascular health, and reducing inflammation throughout the body. The body cannot produce omega-3s efficiently, making dietary intake or supplementation necessary for optimal health.

Overview

Omega-3 fatty acids are a class of polyunsaturated fatty acids (PUFAs) characterized by a double bond at the third carbon from the methyl terminus. The three biologically most important omega-3s are alpha-linolenic acid (ALA, 18:3n-3) from plant sources, eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) from marine sources. ALA is an essential fatty acid that cannot be synthesized de novo, while EPA and DHA can theoretically be produced from ALA through elongation and desaturation — though conversion rates in humans are extremely low (typically <5% for EPA and <0.5% for DHA), making dietary or supplemental intake of preformed EPA and DHA practically essential. DHA constitutes approximately 40% of the polyunsaturated fatty acids in brain gray matter phospholipids and over 60% of fatty acids in retinal photoreceptor outer segments, underscoring its structural importance in neural tissue.

The therapeutic effects of omega-3 fatty acids are mediated through multiple interconnected mechanisms. EPA and DHA serve as substrates for specialized pro-resolving mediators (SPMs) — resolvins, protectins, and maresins — that actively resolve inflammation rather than merely suppressing it, representing a paradigm shift in understanding anti-inflammatory pharmacology. EPA competes with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, reducing production of pro-inflammatory 2-series prostaglandins and 4-series leukotrienes. Cardiovascular benefits include triglyceride reduction (30–50% at pharmacological doses), anti-arrhythmic effects, improved endothelial function, and reduced platelet aggregation. The REDUCE-IT trial demonstrated a 25% relative risk reduction in cardiovascular events with high-dose EPA (icosapent ethyl 4 g/day). Neurologically, DHA is critical for synaptic membrane fluidity, neurotransmitter receptor function, and BDNF expression, with observational data linking higher omega-3 status to reduced risk of cognitive decline and depression.

Standard supplemental doses range from 1–4 g combined EPA/DHA daily, with higher EPA ratios (2:1 or greater) preferred for mood and inflammation, and higher DHA ratios for cognitive and neurological support. Omega-3s are frequently combined with curcumin for synergistic anti-inflammatory effects, vitamin D for immune and mood support, and phosphatidylserine for cognitive enhancement. Fish oil, krill oil, and algal oil are the primary delivery forms, with triglyceride and phospholipid forms showing superior bioavailability to ethyl esters. Side effects are generally mild and include fishy aftertaste, mild gastrointestinal discomfort, and a theoretical (but clinically negligible at standard doses) increase in bleeding time.

Mechanism of Action

Omega-3 polyunsaturated fatty acids, primarily eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), exert their effects through multiple interconnected mechanisms. Upon dietary intake, EPA and DHA are incorporated into cell membrane phospholipids, partially replacing arachidonic acid (AA). This displacement reduces the availability of AA as substrate for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, decreasing production of pro-inflammatory prostaglandins (PGE2), thromboxanes (TXA2), and leukotrienes (LTB4). When EPA and DHA are themselves metabolized by these enzymes, they produce less inflammatory or anti-inflammatory eicosanoids, including 3-series prostaglandins and 5-series leukotrienes.

Critically, EPA and DHA serve as precursors for specialized pro-resolving mediators (SPMs): EPA generates E-series resolvins, while DHA produces D-series resolvins, protectins (including neuroprotectin D1), and maresins. These SPMs actively promote resolution of inflammation by enhancing macrophage phagocytosis of apoptotic cells and debris, reducing neutrophil infiltration, and lowering pro-inflammatory cytokine production. This represents an active resolution process rather than merely suppressing inflammatory initiation.

At the signaling level, omega-3 fatty acids activate the anti-inflammatory receptor GPR120 (FFA4) on macrophages and adipocytes, triggering beta-arrestin-2-mediated suppression of NF-kB and JNK pathways. They also serve as ligands for peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha), modulating gene expression related to lipid metabolism and inflammation. DHA enrichment in neuronal membranes influences membrane fluidity, lipid raft organization, and the function of embedded receptors and ion channels, contributing to neuroprotective effects.

Reconstitution Calculator

Research

Safety Profile

Common side effects include fishy aftertaste, gastrointestinal upset, and loose stools. High doses (above 3g/day) may increase bleeding risk, particularly in individuals taking anticoagulant or antiplatelet medications. People with fish or shellfish allergies should use caution with fish-derived supplements, and omega-3s should be discontinued before surgical procedures.

Pharmacokinetic Profile